Overall summary of adverse events (treated set).

aPatients were randomised 2:2:1 to the tiotropium Respimat 5 μg, tiotropium Respimat 2.5 μg and placebo Respimat groups, respectively. bAs determined by the investigator. cElevation of aspartate aminotransferase and/or alanine aminotransferase ≥3 × upper limit of normal combined with elevated total bilirubin ≥2 × upper limit of normal at the same visit. dAsthma worsening. AE, adverse event. Overall summary of adverse events (treated set).